NEW YORK (GenomeWeb News) - Gentris has entered into an exclusive 10-year agreement with Kyoto-based Falco Biosystems to develop Japan’s first Good Laboratory Practice-compliant pharmacogenomics laboratory, Gentris announced today.

 

The partnership will be called “Gentris Japan.” Japan is the world’s second-largest pharmaceutical market after the US, Gentris said, adding drug companies in the country are increasingly looking to add pharmacogenomics into their drug-development programs.